The classical and updated models of androgen receptor nucleocytoplasmic trafficking

This mini-review covers the classical model of androgen receptor (AR) nucleocytoplasmic trafficking and provides an overview of new data that updates the existing paradigm. The classical model of androgen receptor trafficking involves AR translocating to the nucleus in the presence of androgens and subsequently being exported back to the cytoplasm following the withdrawal of androgens. New data challenges and updates the fate of nuclear AR. In the updated model, the AR can be imported into the nucleus in the absence of androgens and nuclear AR is degraded, not exported. Further, androgens can enhance AR nuclear import and inhibit AR degradation in the nucleus; androgen withdrawal causes nuclear AR degradation, but not export. Enhanced androgen-independent AR nuclear localization and AR nuclear stability may be a hallmark of castration-resistant prostate cancer (CRPC). Further characterization of AR trafficking may aid in the development of new therapies for patients with CRPC.

Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer

Nuclear localization of the androgen receptor (AR) is necessary for its activation as a transcription factor. Defining the mechanisms regulating AR nuclear localization in androgen-sensitive cells and how these mechanisms are dysregulated in castration-resistant prostate cancer (CRPC) cells is fundamentally important and clinically relevant. According to the classical model of AR intracellular trafficking, androgens induce AR nuclear import and androgen withdrawal causes AR nuclear export. The present study has led to an updated model that AR could be imported in the absence of androgens, ubiquitinated, and degraded in the nucleus. Androgen withdrawal caused nuclear AR degradation, but not export. In comparison with their parental androgen-sensitive LNCaP prostate cancer cells, castration-resistant C4-2 cells exhibited reduced nuclear AR polyubiquitination and increased nuclear AR level. We previously identified 3-(4-chlorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole (CPPI) in a high-throughput screen for its inhibition of androgen-independent AR nuclear localization in CRPC cells. The current study shows that CPPI is a competitive AR antagonist capable of enhancing AR interaction with its E3 ligase MDM2 and degradation of AR in the nuclei of CRPC cells. Also, CPPI blocked androgen-independent AR nuclear import. Overall, these findings suggest the feasibility of targeting androgen-independent AR nuclear import and stabilization, two necessary steps leading to AR nuclear localization and activation in CRPC cells, with small molecule inhibitors.